当归芍药散对新型冠状病毒肺炎的临床疗效及其作用机制的网络药理学研究

Clinical efficacy of Danggui Shaoyao Power in COVID-19 and network pharmacology study of its mechanism

为探讨当归芍药散对新型冠状病毒肺炎(COVID-19)的临床疗效及其作用机制,随机选取2020年1月20日~3月20日武汉协和医院收治的100例COVID-19患者作为研究对象,观察当归芍药散联合常规治疗前后患者的基本体征、主要症状、实验室指标、核酸转阴、CT影像学的变化情况,发现以上症状及指标均较前明显好转。同时运用网络药理学分析当归芍药散治疗COVID-19的潜在作用靶点,得到作用靶点18个,GO功能富集180条目,KEGG通路富集109条。结果提示当归芍药散可能通过多靶点、多通路发挥抗病毒、抗炎、抗氧化等作用,进而达到治疗COVID-19的效果。

To explore the clinical efficacy and mechanism of Danggui Shaoyao Powder in coronavirus disease 2019(COVID-19),we collected and analyzed the clinical data containing basic signs,main symptoms,laboratory indicators,nucleic acid negative conversion,and CT imaging before and after Danggui Shaoyao Powder combined with conventional treatment of 100 COVID-19 patients admitted to Wuhan Union Hospital from January 20 to March 20,2020.The results showed that the clinical symptoms and laboratory indicators of these patients were significantly better than before.At the same time,we analyzed the potential targets of Danggui Shaoyao Powder in the treatment of COVID-19 through network pharmacology.Then we found 18 targets,180 items of GO function enrichment,and 109 items of KEGG pathway enrichment.The results suggested that Danggui Shaoyao Powder exerted its therapeutic effects in COVID-19 by modulating multiple targets and pathways,including anti-virus,anti-inflammation,and anti-oxidation.